

3. Practice Bulletin No. 119: Female Sexual Dysfunction. *Obstetrics & Gynecology*. 2011;117(4):996. doi:10.1097/AOG.0b013e31821921ce.
4. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. *N Engl J Med*. 2007;357(8):762-774. doi:10.1056/NEJMoa067423
5. Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*. 2006;6(1):177. doi:10.1186/1471-2458-6-177.
6. Moshesh M, Olshan AF, Saldana T, et al. Examining the relationship between uterine fibroids and dyspareunia among premenopausal women in the United States. *J Sex Med*. 2014;11(3):800-808. doi:10.1111/jsm.12425.
7. Jozifkova E. Consensual sadomasochistic sex (BDSM): the roots, the risks, and the distinctions between BDSM and violence. *Curr Psychiatry Rep*. 2013;15(9):392. doi:10.1007/s11920-013-0392-1.
8. Yong PJ, Sadownik L, Brotto LA. Concurrent deep-superficial dyspareunia: prevalence, associations, and outcomes in a multidisciplinary vulvodynia program. *J Sex Med*. 2015;12(1):219-227. doi:10.1111/jsm.12729.
9. Pazmany E, Bergeron S, Van Oudenhove L, et al. Body image and genital self-image in pre-menopausal women with dyspareunia. *Arch Sex Behav*. 2013;42(6):999-1010. doi:10.1007/s10508-013-0102-4.
10. Fait T. Menopauzální genitourinární syndrom: těžký komunikační problém, snadná léčba. *Časopis lékařů českých*. 2019;158(3-4):101-106.
11. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. *American Journal of Obstetrics and Gynecology*. 1989;160(1):176-181. doi:10.1016/0002-9378(89)90114-2.
12. Ulmsten U, Ekman G, Giertz G, et al. Different biochemical composition of connective tissue in continent and stress incontinent women. *Acta Obstetrica et Gynecologica Scandinavica*. 1987;66(5):455-457. doi:10.3109/00016348709022054.
13. The Effects of Estrogens and Gestagens on the Urethral Pressure Profile in Urinary Continent and Stress Incontinent Women: *Acta Obstetrica et Gynecologica Scandinavica*. 2024;59:3. <https://www.tandfonline.com/doi/abs/10.3109/00016348009155409>.
14. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. *Climacteric*. 2012;15(3):267-274. doi:10.3109/13697137.2012.657589.
15. Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. *Climacteric*. 2015;18(2):226-232. doi:10.3109/13697137.2014.954996.
16. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause*. 2016;23(3):243-256. doi:10.1097/GME.0000000000000571.
17. FDA approves Intrarosa for postmenopausal women experiencing pain during sex. FDA. 2024. <https://www.fda.gov/news-events/press-announcements/fda-approves-intrarosa-postmenopausal-women-experiencing-pain-during-sex>.
18. Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. *Am Fam Physician*. 2014;90(7):465-470.
19. Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation." FDA. Published March 24, 2020. Accessed January 27, 2024. <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims>.

27. ročník Moravského urologického sympozia



Aktuální informace sledujte na
www.kongresurologie.cz

12.–13. 5. 2025
Hotel Sepetná

MÍSTO KONÁNÍ
Hotel Sepetná
Ostravice, www.sepetna.cz

